Professional Documents
Culture Documents
Clinical Guidelines - Guthrie-2012 - Adapting Clinical Guidelines To Take Account of Multimorbidity
Clinical Guidelines - Guthrie-2012 - Adapting Clinical Guidelines To Take Account of Multimorbidity
, and Mercer,
S.W. (2012) Adapting clinical guidelines to take account of
multimorbidity. British Medical Journal, 345 (oct04 ). e6341-e6341. ISSN
0959-535X
http://eprints.gla.ac.uk/70694/
Page 1 of 5
Analysis
ANALYSIS
Adapting clinical guidelines to take account of
multimorbidity
Care of patients with multimorbidity could be improved if new technology is used to bring together
guidelines on individual conditions and tailor advice to each patients circumstances, say Bruce
Guthrie and colleagues
1
Bruce Guthrie professor of primary care medicine , Katherine Payne professor of health economics ,
3
1
Phil Alderson associate director , Marion E T McMurdo professor of ageing and health , Stewart
4
W Mercer professor of primary care research
Population Health Sciences Division, Medical Research Institute, University of Dundee, Dundee DD2 4BF, UK ; 2School of Community Based
Medicine, University of Manchester, Manchester, UK; 3Centre for Clinical Practice, National Institute for Health and Clinical Excellence, Manchester,
UK ; 4University of Glasgow, Glasgow, UK
1
Subscribe: http://www.bmj.com/subscribe
Page 2 of 5
ANALYSIS
The table shows the NNT for our hypothetical patient for the
two preventive drug regimens recommended. Both regimens
are highly effective, but the benefits of oral anticoagulation on
prevention of stroke and total mortality are greater and accrue
more rapidly than treatment of hypertension with up to three
drugs. In many circumstances, clinicians would recommend
both, but actual treatment will vary depending on the patients
preferences; these are particularly important for treatments such
as warfarin that require intensive monitoring and modification
of lifestyle.5
Decision making therefore has to appropriately balance clinical
evidence of benefit and harm, and individual preferences.
Critically, both of these may change over time, with the
development of ischaemic heart disease making control of
hypertension relatively more important, or the development of
a life limiting cancer making it less important. Providing
meaningful comparative data on likely benefit and harm in an
individual is not straightforward, but this is again an argument
for systematically embedding what data exist in individualised
guidelines to support clinicians and patients in decision making
rather than providing virtually no data on comparative
effectiveness as currently happens.
Page 3 of 5
ANALYSIS
Conclusion
Clinical decision making requires judgment because evidence
is imperfect, and treatment has to consider patient circumstances,
preferences, and the available healthcare budget. From this
perspective, guidelines will always have limitations, but existing
guidelines can and should be improved as we suggest.
Shaun Treweek, Colin McCowan, Tim Stokes, Matt Sutton, and Martin
Wilson contributed to developing the ideas presented here during the
writing of the grant proposal. The multimorbidity data reported were
provided by the Primary Care Clinical Informatics Unit (PCCIU) at the
University of Aberdeen. The original analysis of these data was funded
by the Chief Scientist Office of the Scottish Government Health
Directorates (Applied Research Programme Grant ARPG/07/1).
Contributors and sources: BG, SW, and MM are academic general
practitioners or geriatricians with an interest in appropriate care for
people with multimorbidity. PA and KP both have expertise in guideline
development. BG, KP, and PA had the original idea while writing a grant
application to develop methods for accounting for multimorbidity in
guidelines (National Institutes for Health Services and Delivery Research
programme 11/2003/27), and developed it for this paper with SW and
MM. BG wrote the first draft, and all authors contributed to the editing
and writing of the final paper. The views expressed here do not
necessarily reflect those of the authors funding bodies or employers.
BG is the guarantor.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
Related links
bmj.com
Subscribe: http://www.bmj.com/subscribe
Page 4 of 5
ANALYSIS
Table
Table 1| Recommended medium to long term drug treatment for a 76 year old woman with hypertension, atrial fibrillation, osteoarthritis,
Recommended treatment
Hypertension
11
Oral anticoagulation
Aspirin if patient declines oral anticoagulation
Osteoarthritis in
knees and hands
with moderate pain
and functional
limitation13
Topical NSAID
Second line analgesia if first line ineffective:
Oral NSAID + PPI
Oral opiate
Persistent
moderate
depression10 14
ACE=angiotensin converting enzyme; NSAID= non-steroidal anti-inflammatory drug; SSRI= selective serotonin reuptake inhibitor; PPI=proton pump inhibitor.
*Assumes annual stroke risk of 4% based on CHADS2 score of 2.
Subscribe: http://www.bmj.com/subscribe
Page 5 of 5
ANALYSIS
Figure
Subscribe: http://www.bmj.com/subscribe